Wegovy Weight-Loss Pill Now Available in Utah

Oral semaglutide treatment could expand access and lower costs, say medical experts.

Published on Mar. 12, 2026

Got story updates? Submit your updates here. ›

The FDA has approved the first pill form of the weight-loss drug semaglutide, known as Wegovy. Medical professionals believe the oral option will significantly increase access to treatment by removing common barriers like fear of needles and lifestyle concerns around injectable medications. The new pill form is also expected to be more affordable than injectable versions, further broadening participation in medically supervised weight-loss programs.

Why it matters

The availability of an oral semaglutide treatment could have far-reaching public health benefits by making weight-loss medication more accessible and affordable. Increased adoption of these therapies is predicted to lead to population-wide reductions in obesity-related conditions like heart disease, diabetes, and joint problems, translating to dramatic healthcare savings.

The details

Wegovy in pill form was approved by the FDA in December 2025 and hit the market in January 2026. Unlike injectable semaglutide medications like Ozempic and Wegovy, the new oral version does not require refrigeration, making it easier to store, transport, and ship. Physicians also expect the pill form to be more affordable due to reduced manufacturing complexity and shipping costs. While semaglutide therapies are primarily approved for weight loss, they also help reduce cardiovascular risks in adults with obesity or overweight.

  • The FDA approved the pill form of Wegovy on December 22, 2025.
  • Wegovy in pill form became available on the market in January 2026.

The players

Wegovy

A prescription weight-loss medication that contains the active ingredient semaglutide. Wegovy is the first daily oral GLP-1 receptor agonist approved for weight loss in the United States.

Dr. Joshua Schmidt

A physician at Prestige Men's Health in Holladay, Utah, who provides supervised weight-loss treatments using injectable and now oral semaglutide medications.

Novo Nordisk

The pharmaceutical company that manufactures Wegovy and received FDA approval for the oral formulation of the weight-loss drug.

John Sharretts, M.D.

The director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research, who commented on the approval of Wegovy for weight loss and cardiovascular risk reduction.

Got photos? Submit your photos here. ›

What they’re saying

“It's extremely promising. There are a lot of patients who simply cannot or will not do injections — whether it's fear of needles, coordination issues, or lifestyle concerns. Pill form opens the door for those patients.”

— Dr. Joshua Schmidt, Physician, Prestige Men's Health (Gephardt Daily)

“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight. This patient population has a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health.”

— John Sharretts, M.D., Director, Division of Diabetes, Lipid Disorders, and Obesity, FDA (Gephardt Daily)

What’s next

As demand for oral semaglutide continues to grow, healthcare providers say the focus will remain on supervision, proper dosing, and long-term lifestyle changes to help patients achieve their weight-loss goals.

The takeaway

The availability of an oral formulation of the weight-loss drug semaglutide has the potential to significantly expand access to medically supervised weight-loss treatments by removing common barriers like fear of needles and making the therapy more affordable. This could lead to population-wide reductions in obesity-related health conditions and substantial healthcare savings.